One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Psoriasis Drugs Market

[ 英語タイトル ] Psoriasis Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

Product Code : MDHC0088848
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 111
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Eli Lilly and Company
- Pfizer Inc.
- Johnson and Johnson (Janssen Biotech Inc.)
- Celgene Corporation
- Takeda Pharmaceutical Company Limited
- Stiefel Laboratories Inc.
- Novartis AG
- Amgen Inc.
- Biogen Idec
- AbbVie Inc.

[Report Description]

The psoriasis drugs market is expected to register a CAGR of 9.3% during the forecast period. The primary factors that are responsible for the growth of this market include the increasing disease burden and demand for psoriasis medicines in emerging economies and the increase in psoriasis research and pipeline drugs.

- Among all these factors, one of the factors expected to have a major impact on the market growth is the increasing use of combination therapies. Research is continuing on the combination therapies approach. However, studies conducted suggest that it often eases psoriasis symptoms more effectively than either treatment by themselves. Biologics usually take a while to work.
- Combining a biologic with a faster-acting systemic drug, such as cyclosporine, is usually much more effective and safer. With faster, longer-lasting results and fewer side effects, requiring lower doses, many doctors are prescribing combination therapies, which is, in turn, expected to drive the psoriasis drugs market. However, factors such as the side effects of existing medications may have a negative impact on the market growth.

Key Market Trends

Interleukin Inhibitors is Expected to Grow with a High CAGR in the Forecast Period

Interleukin inhibitors may witness the fastest growth during the forecast period, and the factors aiding these interleukin inhibitors are their improved safety and efficacy when compared to other psoriasis drugs, and their increased adoption among end users. Drugs, like Secukinumab and Ustekinumab, among others, are aiding the market growth as the usage of drugs is increasing each year. Another benefit of the IL-mode of therapy is for the patients who are intolerant or contraindicated to TNF-α inhibitor therapy.

North America Dominates the Market and is Expected to do so in the Forecast Period

North America currently dominates the market for psoriasis drugs, and it is expected to continue having a stronghold for a few more years. In North America, the United States holds the largest market share. This can be majorly attributed to the increasing prevalence of psoriasis, the presence of favorable government initiatives, the presence of developed healthcare infrastructure, high adoption of therapeutics, and the presence of key drug manufacturers. All these factors are expected to propel the market in the United States.

Competitive Landscape

The psoriasis drugs market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The rising number of patients is attracting a few other players to enter the market, and a few smaller players are also expected to enter the market in the future, who may hold a substantial share. Companies are focused on business expansion in developing regions or emerging markets, such as India, China, and South Korea, by adopting strategies, including alliances and acquisitions for the development of novel products. Some of the major players of the market are Eli Lilly and Company, Pfizer Inc., Johnson and Johnson (Janssen Global Services LLC), Novartis AG, and Amgen Inc., among others.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Disease Burden and Demand for Psoriasis Medicines in Emerging Economies
4.2.2 Increasing Use of Combination Therapies
4.2.3 Increase in Psoriasis Research and Pipeline Drugs
4.3 Market Restraints
4.3.1 Adverse Side Effects of Existing Medications
4.3.2 High Cost of Psoriasis Treatments
4.3.3 Extensive Drug Development and Approval Process
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type of Treatment
5.1.1 Biologic Drugs
5.1.2 Small Molecule Systemic Drugs
5.1.3 Tropical Therapies
5.2 By Mechanism of Action
5.2.1 TNF Alpha Inhibitors Etanercept Certolizumab Pegol Adalimumab Infiximab Golimumab
5.2.2 PDE4 Inhibitors Apremilast
5.2.3 Interleukin Inhibitors Secukinumab Ustekinumab Other Interleukin Inhibitors
5.2.4 Other Mechanisms of Action
5.3 By Route of Administration
5.3.1 Oral
5.3.2 Parenteral
5.3.3 Topical
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Eli Lilly and Company
6.1.2 Pfizer Inc.
6.1.3 Johnson and Johnson (Janssen Biotech Inc.)
6.1.4 Celgene Corporation
6.1.5 Takeda Pharmaceutical Company Limited
6.1.6 Stiefel Laboratories Inc.
6.1.7 Novartis AG
6.1.8 Amgen Inc.
6.1.9 Biogen Idec
6.1.10 AbbVie Inc.




Recommended reports